IsoRay Company Profile (NYSEMKT:ISR)

About IsoRay (NYSEMKT:ISR)

IsoRay logoIsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:ISR
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $31.35 million
  • Outstanding Shares: 55,017,000
Average Prices:
  • 50 Day Moving Avg: $0.57
  • 200 Day Moving Avg: $0.58
  • 52 Week Range: $0.48 - $1.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 56.99
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $4.37 million
  • Price / Sales: 7.17
  • Book Value: $0.25 per share
  • Price / Book: 2.31
  • EBIDTA: ($5,700,000.00)
  • Average Volume: 114,156 shs.
  • Short Ratio: 17.26

Frequently Asked Questions for IsoRay (NYSEMKT:ISR)

What is IsoRay's stock symbol?

IsoRay trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ISR."

How were IsoRay's earnings last quarter?

IsoRay, Inc. (NYSEMKT:ISR) posted its earnings results on Wednesday, May, 10th. The company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $1.28 million for the quarter. View IsoRay's Earnings History.

Where is IsoRay's stock going? Where will IsoRay's stock price be in 2017?

1 equities research analysts have issued 12-month price objectives for IsoRay's shares. Their predictions range from $3.00 to $3.00. On average, they anticipate IsoRay's stock price to reach $3.00 in the next twelve months. View Analyst Ratings for IsoRay.

Who are some of IsoRay's key competitors?

How do I buy IsoRay stock?

Shares of IsoRay can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of IsoRay stock cost?

One share of IsoRay stock can currently be purchased for approximately $0.57.

Analyst Ratings

Consensus Ratings for IsoRay (NYSEMKT:ISR) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00

Analysts' Ratings History for IsoRay (NYSEMKT:ISR)
DateFirmActionRatingPrice TargetDetails
5/11/2017Maxim GroupSet Price TargetBuy$3.00View Rating Details
(Data available from 5/26/2015 forward)


Earnings History for IsoRay (NYSEMKT:ISR)
Earnings by Quarter for IsoRay (NYSEMKT:ISR)
Earnings History by Quarter for IsoRay (NYSEMKT:ISR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q3 2017($0.02)$1.28 millionViewN/AView Earnings Details
2/8/2017Q2 2017($0.03)$1.03 millionViewN/AView Earnings Details
11/9/2016Q1 2017($0.03)$1.08 millionViewN/AView Earnings Details
9/8/2016Q416($0.02)$1.12 millionViewN/AView Earnings Details
5/10/2016Q316($0.02)$1.16 million$1.20 millionViewN/AView Earnings Details
2/9/2016Q216($0.02)$1.07 million$1.19 millionViewN/AView Earnings Details
11/10/2015Q116($0.01)($0.02)$1.04 million$1.46 millionViewN/AView Earnings Details
9/15/2015Q4($0.01)($0.02)$1.34 millionViewN/AView Earnings Details
5/18/2015Q3($0.01)($0.02)$1.13 million$1.16 millionViewN/AView Earnings Details
2/18/2015Q215($0.02)($0.02)$1.07 millionViewN/AView Earnings Details
5/16/2014Q314($0.03)($0.05)$1.13 million$1.13 millionViewN/AView Earnings Details
11/14/2013Q1($0.06)$1.06 million$1.05 millionViewN/AView Earnings Details
5/15/2013Q313($0.03)($0.02)$1.12 million$1.25 millionViewN/AView Earnings Details
2/14/2013Q2 2013($0.03)($0.03)$1.32 million$0.95 millionViewN/AView Earnings Details
11/14/2012Q113($0.03)($0.03)$1.55 million$1.06 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IsoRay (NYSEMKT:ISR)
Current Year EPS Consensus Estimate: $-0.0900 EPS
Next Year EPS Consensus Estimate: $0.0100 EPS


Dividend History for IsoRay (NYSEMKT:ISR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IsoRay (NYSEMKT:ISR)
Insider Trades by Quarter for IsoRay (NYSEMKT:ISR)
Insider Trades by Quarter for IsoRay (NYSEMKT:ISR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/10/2017Thomas C LavoyCEOBuy20,000$0.53$10,600.00View SEC Filing  
1/4/2017Philip J VitaleDirectorBuy20,000$0.66$13,200.00View SEC Filing  
12/8/2016Alan HoffmannDirectorBuy20,000$0.57$11,400.00View SEC Filing  
11/17/2016Thomas C LavoyCEOBuy20,000$0.60$12,000.00View SEC Filing  
3/17/2016Thomas C LavoyCEOBuy13,294$0.90$11,964.60View SEC Filing  
3/11/2016Philip J VitaleDirectorBuy10,000$0.93$9,300.00View SEC Filing  
3/11/2016Thomas C LavoyCEOBuy36,706$0.89$32,668.34View SEC Filing  
3/8/2016Michael W MccormickDirectorBuy22,000$0.87$19,140.00View SEC Filing  
11/12/2015Dwight William BabcockCEOBuy25,000$1.27$31,750.00View SEC Filing  
6/9/2015Dwight William BabcockCEOBuy10,000$1.53$15,300.00View SEC Filing  
3/6/2015Thomas C LavoyDirectorBuy10,000$1.66$16,600.00View SEC Filing  
3/5/2015Philip J VitaleDirectorBuy10,000$1.80$18,000.00View SEC Filing  
3/3/2015Dwight William BabcockCEOBuy10,029$1.51$15,143.79View SEC Filing  
11/1/2013Dwight William BabcockCEOBuy25,000$0.53$13,250.00View SEC Filing  
11/28/2012Thomas C LavoyDirectorBuy18,100$0.49$8,869.00View SEC Filing  
11/21/2012Dwight William BabcockCEOBuy10,100$0.40$4,040.00View SEC Filing  
11/19/2012Dwight William BabcockCEOBuy4,800$0.37$1,776.00View SEC Filing  
11/19/2012Robert R KauffmanDirectorBuy25,000$0.38$9,500.00View SEC Filing  
11/16/2012Dwight William BabcockCEOBuy35,100$0.42$14,742.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IsoRay (NYSEMKT:ISR)
Latest Headlines for IsoRay (NYSEMKT:ISR)
DateHeadline logoIsoRay, Inc. (ISR) PT Set at $3.00 by Maxim Group - May 13 at 5:50 PM logoIsoRay, Inc. (ISR) Releases Quarterly Earnings Results - May 11 at 2:46 PM logoForm 8-K IsoRay, Inc. For: May 10 - - May 10 at 11:17 PM logoIsoRay Announces Third Quarter Fiscal 2017 Financial Results - May 10 at 1:14 PM logoIsoRay, Inc. (ISR) - May 8 at 8:02 AM logoIsoRay (ISR) Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology ... - - May 5 at 5:59 PM logoIsoRay (ISR) Getting Favorable Press Coverage, Report Shows - May 4 at 12:42 PM logoIsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled "Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131" - May 3 at 10:37 PM logoETFs with exposure to IsoRay, Inc. : April 27, 2017 - April 27 at 6:35 PM logoIsoRay, Inc. to Present at the Planet MicroCap Showcase 2017 - April 18 at 10:59 AM logoETFs with exposure to IsoRay, Inc. : April 7, 2017 - April 7 at 5:52 PM logoIsoRay (ISR) Announces Final Court Approval of Class Action Settlement - - March 10 at 7:13 PM logoISORAY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 10 at 7:13 PM logoIsoRay Announces Final Court Approval of Class Action Settlement - March 9 at 8:39 PM logo4:06 pm IsoRay announces that the previously announced Stipulation of Settlement has been approved by the U.S. District Court for the Eastern District of Washington - March 9 at 8:39 PM logoIsoRay Announces Second Quarter Fiscal 2017 Financial Results - PR Newswire (press release) - February 9 at 4:48 AM logoIsoRay Announces Second Quarter Fiscal 2017 Financial Results - February 8 at 6:45 PM logoIsoRay, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference - February 2 at 6:42 PM logoISORAY, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers - January 23 at 6:17 PM logoIsoRay's chief financial officer resigns - January 20 at 12:50 AM logoPurcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of ... - PR Newswire (press release) - January 11 at 6:36 PM logoPurcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors - January 11 at 6:36 PM


This page was last updated on 5/26/2017 by Staff